GN-HEARING
16.6.2022 12:02:09 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today announces the most advanced, rechargeable Custom made by ReSound hearing aids . These hearing aids provide all day use, streaming from iPhone and iPad or AndroidTM smartphones, and comfort with superior sound quality, in a stylish design. Custom made by ReSound hearing aids offer medical-grade, customized, full-time hearing support and care, whereas the recently launched Jabra Enhance Plus is intended for people needing occasional hearing support. GN continues to combine expertise from the hearing and audio worlds with the goal to enable millions of people in taking an important step on their hearing health journey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005063/en/
According to research, 58% of people try headphones to help with their hearing, before moving onto hearing aids*. Now they can get a stylish, custom made hearing aid with expertise and support from a hearing care professional. Every ear is different, so each Custom made by ReSound hearing aid is meticulously crafted in a series of highly technical, specialized processes. Molded to fit the individuals’ unique ear canal, they can be worn comfortably and confidently all day long.
These new rechargeable hearing aids are the first in the world to come with a customized case containing specially created inserts made to match each hearing aid for a seamless and reliable recharge. They offer up to 24 hours use-time on a single charge – even when streaming – for worry-free, all-day use without the fear of batteries running out on the go. Users can wear glasses or face masks without worrying about them getting snagged on their hearing aids and take hands-free phone and FaceTime calls on their iPhone or iPad** with the touch of a finger.
The new Custom made by ReSound hearing aids provide natural hearing in any situation by allowing users to hear with their own ears, for greater spatial awareness and a truly personalized sound. They deliver up to 30% better speech understanding in noise and 1-2 dB more directional benefit***. The solution incorporates All-Access Directionality which means the hearing aids automatically adjust to surroundings in real time. This enables the brain to select sounds naturally so that no matter the situation, users can enjoy conversations and sounds without being cut off from their surroundings.
GN Hearing CEO, Gitte Aabo explains, “GN Hearing is challenging conventions and setting the stage for an entirely new standard. This new sleek design will make people think again and encourage them to take care of their hearing health by offering the most advanced hearing aid technology in a design they will love.”
The new Custom made by ReSound hearing aids are planned for Regulatory clearance and rolled out globally starting with the US on June 29, 2022, along with the equivalent Beltone Imagine line-up, in both ITC (In-The-Canal) and ITE (In-the-Ear) styles. The Custom made by ReSound hearing aids offer a great choice of colors and will be available in a new In-styleTM anthracite color or Blend-inTM hair and skin tones.
For more information, visit the ReSound website.
*58% of non-hearing aid users (n=419) use headphones or earbuds to help with their hearing, trying other devices before exploring hearing aids. GN Fidelity End User multi-market study, 2021, internal
**Hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation), with software updates iOS 15.3 and iPadOS 15.3 or later.
*** Compared to ReSound LiNX Quattro products, Groth J. (2020). The evolution of the binaural hearing strategy: All Access Directionality and Ultra Focus. ReSound white paper
– ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook .
© 2022 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom